Your shopping cart is currently empty

ALM301 is a highly specific, orally active AKT inhibitor that acts on AKT1 (IC50: 0.13 μM), AKT2 (IC50: 0.09 μM) and AKT3 (IC50: 2.75 μM). ALM301 inhibits AKT phosphorylation in vitro and has a regulatory effect on downstream signalling. ALM301 exhibits inhibitory effects on cancer cell proliferation and tumor growth.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,370 | 8-10 weeks | 8-10 weeks | |
| 50 mg | $1,790 | 8-10 weeks | 8-10 weeks | |
| 100 mg | $2,890 | 8-10 weeks | 8-10 weeks |
| Description | ALM301 is a highly specific, orally active AKT inhibitor that acts on AKT1 (IC50: 0.13 μM), AKT2 (IC50: 0.09 μM) and AKT3 (IC50: 2.75 μM). ALM301 inhibits AKT phosphorylation in vitro and has a regulatory effect on downstream signalling. ALM301 exhibits inhibitory effects on cancer cell proliferation and tumor growth. |
| Targets&IC50 | Akt3:2.75 μM, AKT1:0.13 μM, Akt2:0.09 μM |
| Molecular Weight | 415.48 |
| Formula | C25H25N3O3 |
| Cas No. | 1313439-71-2 |
| Smiles | CCN1C(=O)COc2nc(-c3ccc(cc3)[C@@]3(N)C[C@H](O)C3)c(cc12)-c1ccccc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.